Tasisulam 50 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier Page
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier Page
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier Page
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier Page
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier Page
Dalcetrapib, a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.
More Information Supplier Page
Dalcetrapib, a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.
More Information Supplier Page
Succinobucol is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.
More Information Supplier Page
Succinobucol is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.
More Information Supplier Page
Succinobucol is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.
More Information Supplier Page
Succinobucol is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.
More Information Supplier Page